/l. Leukocyte alkaline phosphatase score was only 2. BM morphology indicated CML in chronic phase with a Philadelphia chromosome. Molecular examination corroborated the diagnosis, showing a BCR-ABL transcript (b2a2 subtype). Imatinib 400 mg daily was prescribed. The patient had a good response and achieved complete hematologic response within 3 months, complete cytogenetic response in 6 months and major molecular response in 12 months (Table 1) .
Unfortunately, pancytopenia with hemorrhagic episodes occurred in January 2008. BM study revealed progression to the blastic phase, with myeloid blast cells accounting for 30.8%. Quantitative RT-PCR also showed an increase in the BCR-ABL1 level. A cytogenetic study showed clonal evolution with an additional t(8;21)(q22;q22) abnormality (Table 1) . Molecular analysis concurred with the presence of the AML1-ETO transcript, which was not detected previously ( Figure 1 ). There were no mutations found in BCR-ABL1, c-KIT and NPM1 in chronic phase or blastic phase samples. The imatinib dose was escalated to 400 mg twice daily, which resulted in no obvious response 2 weeks later. The patient was then switched to nilotinib 400 mg twice daily in late January 2008. Hematologic and major cytogenetic responses were achieved 3 months later. However, recurrence of the blastic phase occurred in July 2008. The patient was then switched to dasatinib 100 mg daily.
Owing to the advanced status of CML, the patient underwent MUD SCT with a conditioning regimen of TBI plus 120 mg/m 2 CY in September 2008. The transplanted cell dose was 11.1 Â 10 8 /kg (CD34 þ : 14Â 10 6 /kg). He suffered from grade I acute GVHD and fungal infection after engraftment, but responded well to anti-GVHD and anti-fungal agents. He had complete hematologic and cytogenetic response of CML with undetectable BCR-ABL1 and AML1-ETO transcripts after the transplantation (Table 1 and Figure 1 ). He is currently alive 13 months after SCT without the use of any tyrosine kinase inhibitor and with no severe complication of the transplantation.
Although rare, this and previously reported cases imply that t(8;21) can occur in CML as a clonal evolution of the disease. [1] [2] [3] Because neither ABL mutations nor other chromosomal abnormalities were found in this patient, t(8;21) was considered to be the cause of the imatinib failure and disease progression. t(8;21)(q22;q22) with AML1-ETO transcript, also known as RUNX1-CBAF2T1, is designated as a special type of de novo AML according to the WHO classification. The transcript leads to a multifunction protein exerting its influence on cell proliferation, differentiation and survival. 4 However, secondary events beyond AML1-ETO might be required for the leukemia to develop. 4, 5 The synergistic effect of AML1-ETO and BCR-ABL may provide the growth advantage for leukemic transformation and explain its progression in this patient. Compared with the de novo AML with t(8;21), which is supposed to be a good risk profile, CML with this translocation showed rapid disease progression and resistant characteristics. All cases progressed to the blastic phase within 2 years. [1] [2] [3] Even those patients who had already achieved complete cytogenetic response on imatinib therapy, as in our case, proceeded to blastic phase. In addition, no response to high-dose imatinib and nondurable response to nilotinib demonstrated the resistant characteristics of this combination of chromosomal abnormalities. Transplantation seemed to be an effective treatment in this patient, with tolerable side effects.
In summary, we present a rare case with t(8;21) acquired in the blastic phase of CML after complete remission on imatinib therapy. The case demonstrates the characteristics of resistance to tyrosine kinase inhibitors and suggests that SCT may be the only curative treatment for this kind of patient.
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